Advanced SARS-CoV-2 vaccine candidates
| Vaccine name | Clinical trial number | Manufacture | Phase trial | Number of participants | Immunity response | Efficacy | Ref. |
|---|---|---|---|---|---|---|---|
| mRNA-1273 | NCT04470427 | MODERNA/NIAID | 3 | 30,000 | CD4+ T cell activation reported Th1 skewed phenotype | 94.10% | [71] |
| BNT 162b2 | NCT04368728 | BioNTech/Pfizer | 3 | 44,000 | Virus specific Th1 and CD8+ T cell responses reported | 95% | [71] |
| Ad5-nCoV | NCT04526990 | CanSino Biological | 3 | 40,000 | T cell responses were observed in 88% of the participants | - | [71, 72] |
| AZD1222 | NCT04540393 | AstraZeneca | 3 | 30,000 | T cell responses observed in all participants | 62.10% | [71, 73] |
| Sputnik V | NCT04530396 | Gamaleya Research Institute | 3 | 40,000 | CD4+ and CD8+ T cell responses were observed in all participants | - | [71] |
| JNJ-78436735 | NCT04505722 | Janssen Pharmaceutical | 3 | 90,000 | CR4+ T cell responses in 80% of the participants | - | [71, 75] |
| 53coronaVac | NCT04456596 | Sinovac Research & Development Co. | 3 | 8,870 | Not reported | - | [71, 73] |
| BBIBP-CorV | NCT04560881 | Beijing Institute of Biotechnology | 3 | 63,000 | Not reported | 79.38% | [71, 74] |
| BBV152 | CTRI/2020/11/028976 | Bharat Biotech | 3 | 26,000 | Virus specific CD4+ and CD8+ T cell responses reported | - | [71, 73] |
| NVX-CoV2373 | NCT04611802 | Novavax | 3 | 45,000 | CD4+ T cell activation in all tested participants | - | [71, 75] |
| CoVLP | NCT04636697 | Medicago | 3 | 30,612 | Not reported | - | [71, 76] |
Ref.: reference. “-” in the efficacy column mentioned in Table 3 refers to the lack of information/data on that specific vaccine. Information on these clinical trials can be retrieved from https://clinicaltrials.gov/ct2/home
